CD22 and neoplasm: Conversely, negative selection resulted in reduced cytokine levels in response to CD22+ B-ALL, but a quicker ex vivo tumor killing rate with significant enrichment of anti-CD22 CAR Vδ1 and Vδ2 T cells [213].